NZ598370A - Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units - Google Patents

Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units

Info

Publication number
NZ598370A
NZ598370A NZ598370A NZ59837010A NZ598370A NZ 598370 A NZ598370 A NZ 598370A NZ 598370 A NZ598370 A NZ 598370A NZ 59837010 A NZ59837010 A NZ 59837010A NZ 598370 A NZ598370 A NZ 598370A
Authority
NZ
New Zealand
Prior art keywords
pth
week
units
unit dose
administered once
Prior art date
Application number
NZ598370A
Other languages
English (en)
Inventor
Shinichiro Shirae
Yasuo Nakamura
Yuiko Oya
Yoshihide Nozaki
Nobuyuki Kobayashi
Tatsuhiko Kuroda
Hiroki Kato
Masashi Serada
Kazuyoshi Hori
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43732444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ598370(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Priority to NZ617397A priority Critical patent/NZ617397A/en
Publication of NZ598370A publication Critical patent/NZ598370A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ598370A 2009-09-09 2010-09-08 Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units NZ598370A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ617397A NZ617397A (en) 2009-09-09 2010-09-08 Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009208039 2009-09-09
PCT/JP2010/065379 WO2011030774A1 (ja) 2009-09-09 2010-09-08 １回当たり１００～２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤

Publications (1)

Publication Number Publication Date
NZ598370A true NZ598370A (en) 2014-04-30

Family

ID=43732444

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ598370A NZ598370A (en) 2009-09-09 2010-09-08 Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units
NZ617397A NZ617397A (en) 2009-09-09 2010-09-08 Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ617397A NZ617397A (en) 2009-09-09 2010-09-08 Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units

Country Status (16)

Country Link
US (3) US20120252729A1 (enExample)
EP (3) EP2682124B1 (enExample)
JP (13) JPWO2011030774A1 (enExample)
KR (8) KR20120067336A (enExample)
CN (2) CN102470164B (enExample)
AU (1) AU2010293488B2 (enExample)
BR (1) BR112012003511A2 (enExample)
CA (1) CA2772656A1 (enExample)
ES (3) ES2843649T3 (enExample)
IL (1) IL217854A (enExample)
IN (1) IN2012DN00857A (enExample)
MX (1) MX335951B (enExample)
NZ (2) NZ598370A (enExample)
RU (1) RU2564894C2 (enExample)
WO (1) WO2011030774A1 (enExample)
ZA (1) ZA201201720B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616004T3 (es) * 2009-11-18 2017-06-09 Asahi Kasei Pharma Corporation Agente profiláctico y/o agente terapéutico y/o agente supresor de exacerbación para osteortritis de rodilla humana
JP6235219B2 (ja) * 2013-03-21 2017-11-22 旭化成ファーマ株式会社 脊椎椎体間固定術後の骨癒合促進剤
US10394953B2 (en) 2015-07-17 2019-08-27 Facebook, Inc. Meme detection in digital chatter analysis
WO2018144719A1 (en) * 2017-02-01 2018-08-09 The Johns Hopkins University Parathyroid hormone and regeneration of degenerative discs disease
JP2019060866A (ja) * 2017-09-22 2019-04-18 旭化成ファーマ株式会社 液状医薬組成物の体内動態を予測する方法
JP6637220B2 (ja) * 2017-09-22 2020-01-29 旭化成ファーマ株式会社 薬物動態及び／又は安全性に優れるテリパラチド含有液状医薬組成物
US20200289621A1 (en) * 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
WO2020090174A1 (ja) 2018-10-29 2020-05-07 旭化成ファーマ株式会社 週２回の頻度でテリパラチド又はその塩を投与することを特徴とする、骨粗鬆症の予防又は治療方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2505812B2 (ja) 1987-07-10 1996-06-12 旭化成工業株式会社 ｈ―ＰＴＨ（１―３４）凍結乾燥組成物
JP2662842B2 (ja) 1991-12-09 1997-10-15 旭化成工業株式会社 パラサイロイドホルモンの安定化組成物
JPH0873376A (ja) 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
ZA9811127B (en) * 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
AR033639A1 (es) * 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
CA2414966A1 (en) 2000-06-30 2002-01-10 Suntory Limited A pharmaceutical component based on human parathyroid hormone and a pharmaceutical composition for intranasal administration containing the component
JP5042419B2 (ja) * 2001-08-15 2012-10-03 旭化成ファーマ株式会社 骨形成促進剤および骨形成促進組成物
JP4931306B2 (ja) * 2001-09-27 2012-05-16 旭化成ファーマ株式会社 骨形成を安全に促進させる医薬複合剤
JP2007525472A (ja) * 2003-07-04 2007-09-06 ニコメド ダンマーク エイピーエス 経口使用のための副甲状腺ホルモン（ｐｔｈ）含有医薬組成物
US7632813B2 (en) * 2004-04-26 2009-12-15 Ono Pharmaceutical Co., Ltd. Bone densifying agent characterized by use of cathepsin K inhibitor with PTH
CN101151048A (zh) * 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
JP2006241098A (ja) * 2005-03-04 2006-09-14 Univ Kurume 骨量減少症の予防または治療薬
EP2311505B1 (en) * 2006-02-09 2013-11-06 BioMimetic Therapeutics, LLC Compositions and methods for treating bone
DE102006043846A1 (de) * 2006-03-14 2007-09-20 Claudia Zours Wirbelsäulenorthesen
CA2680690A1 (en) * 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
CN101274961A (zh) * 2006-03-30 2008-10-01 天津医科大学 重组人甲状旁腺素相关蛋白
CN101125201A (zh) * 2006-08-17 2008-02-20 石家庄欧意药业有限公司 治疗骨质疏松症或防治由于骨质疏松而导致的骨折的药物组合物及其应用
CN101307105B (zh) * 2008-04-28 2012-08-29 中国药科大学 一种能串联表达和同步酸水解释放的人甲状旁腺素1-34肽类似物及其制备方法和应用

Also Published As

Publication number Publication date
KR20210040171A (ko) 2021-04-12
KR20140130754A (ko) 2014-11-11
ZA201201720B (en) 2012-11-28
JP6522715B2 (ja) 2019-05-29
ES2843649T3 (es) 2021-07-20
RU2564894C2 (ru) 2015-10-10
JP6198346B2 (ja) 2017-09-20
KR102335703B1 (ko) 2021-12-07
US20140357560A1 (en) 2014-12-04
ES2662018T3 (es) 2018-04-05
KR20170089018A (ko) 2017-08-02
EP2682124B1 (en) 2018-02-28
KR20170089017A (ko) 2017-08-02
EP2476429A1 (en) 2012-07-18
JP2017105860A (ja) 2017-06-15
CN103893746A (zh) 2014-07-02
JP6043008B2 (ja) 2016-12-14
EP2682125B1 (en) 2020-11-04
RU2012108635A (ru) 2013-10-20
EP2682125A1 (en) 2014-01-08
JP2016130261A (ja) 2016-07-21
JP2019023234A (ja) 2019-02-14
JP2018024710A (ja) 2018-02-15
AU2010293488B2 (en) 2014-11-27
EP2476429A4 (en) 2013-02-27
JP2017105862A (ja) 2017-06-15
BR112012003511A2 (pt) 2019-09-24
JP2017105863A (ja) 2017-06-15
JP2015157854A (ja) 2015-09-03
MX335951B (es) 2016-01-04
EP2682124A1 (en) 2014-01-08
AU2010293488A1 (en) 2012-03-29
WO2011030774A1 (ja) 2011-03-17
CN102470164A (zh) 2012-05-23
KR20190095552A (ko) 2019-08-14
KR20150021590A (ko) 2015-03-02
IL217854A0 (en) 2012-03-29
NZ617397A (en) 2015-02-27
CN102470164B (zh) 2014-04-09
ES2663322T3 (es) 2018-04-12
MX2012002681A (es) 2012-04-19
JPWO2011030774A1 (ja) 2013-02-07
IN2012DN00857A (enExample) 2015-07-10
JP2017105861A (ja) 2017-06-15
JP6274634B2 (ja) 2018-02-07
KR20200115673A (ko) 2020-10-07
HK1168284A1 (en) 2012-12-28
JP2017105858A (ja) 2017-06-15
JP6301524B2 (ja) 2018-03-28
JP2017105859A (ja) 2017-06-15
JP2017061511A (ja) 2017-03-30
JP6150846B2 (ja) 2017-06-21
US20140249084A1 (en) 2014-09-04
IL217854A (en) 2016-08-31
JP2015147813A (ja) 2015-08-20
KR102424644B1 (ko) 2022-07-25
CA2772656A1 (en) 2011-03-17
US20120252729A1 (en) 2012-10-04
EP2476429B1 (en) 2018-03-07
KR20120067336A (ko) 2012-06-25
JP6275900B2 (ja) 2018-02-07

Similar Documents

Publication Publication Date Title
NZ598370A (en) Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units
JP2014139220A5 (enExample)
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
HK1247838A1 (zh) 骨质疏松症的治疗
PH12014501560A1 (en) Carbamate compounds and of making and using same
EA201590166A8 (ru) Комбинированная терапия для лечения рассеянного склероза
MX337614B (es) Tratamiento de lupus nefritis usando laquinimod.
NZ700824A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
WO2011041478A8 (en) Hematopoietic stem cells for use in the treatment of a kidney injury
RU2013132566A (ru) Терапевтическое средство от грыжи межпозвоночного диска
RU2017120184A (ru) Лекарства для замедления течения болезни паркинсона
PH12012500773A1 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
SA113340494B1 (ar) تركيبة لعلاج اضطرابات أيضية
WO2011044523A3 (en) Compositions and methods for treating obesity
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
MX2013003523A (es) Composicion farmaceutica de dosis baja.
PH12012502093A1 (en) Composition for preventing or treating osteoporosis, and manufacturing method therefor
IN2014DN09779A (enExample)
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
IL250852B (en) Periodontal preparation
MX2012003892A (es) Agente preventivo y/o agente terapeutico y/o agente supresivo del agravamiento para la artritis humana deformante.
NZ613264A (en) Use of vitamin k for weight maintenance and weight control
MX2018005876A (es) Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas.
BMJ Group Annual zoledronic acid for osteoporosis

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 SEP 2017 BY CPA GLOBAL

Effective date: 20140910

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2018 BY CPA GLOBAL

Effective date: 20170727

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2019 BY CPA GLOBAL

Effective date: 20180802

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2020 BY CPA GLOBAL

Effective date: 20190801

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2021 BY CPA GLOBAL

Effective date: 20200730

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2022 BY CPA GLOBAL

Effective date: 20210729

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2023 BY CPA GLOBAL

Effective date: 20220729

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2024 BY CPA GLOBAL

Effective date: 20230727

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240801

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250731